<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37499070</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2641-7650</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Kidney360</Title><ISOAbbreviation>Kidney360</ISOAbbreviation></Journal><ArticleTitle>Implications of Incomplete Immunostaining in Membranous Lupus Nephritis.</ArticleTitle><Pagination><StartPage>868</StartPage><EndPage>869</EndPage><MedlinePgn>868-869</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.34067/KID.0000000000000191</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyata</LastName><ForeName>Kana N</ForeName><Initials>KN</Initials><Identifier Source="ORCID">0000-0001-6486-4666</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Saint Louis University, Saint Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nast</LastName><ForeName>Cynthia C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-8243-9073</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney360</MedlineTA><NlmUniqueID>101766381</NlmUniqueID><ISSNLinking>2641-7650</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Kidney360. 2023 Jul 1;4(7):935-942</RefSource><PMID Version="1">37257088</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015433" MajorTopicYN="Y">Glomerulonephritis, Membranous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>C.C. Nast reports the following&#x2014;consultancy: BioCryst Pharmaceuticals and advisory or leadership role: BioCryst Pharmaceuticals. The remaining author has nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>19</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37499070</ArticleId><ArticleId IdType="pmc">PMC10374139</ArticleId><ArticleId IdType="doi">10.34067/KID.0000000000000191</ArticleId><ArticleId IdType="pii">02200512-202307000-00002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ward F, Bargman JM. Membranous lupus nephritis: the same, but different. Am J Kidney Dis. 2016;68(6):954&#x2013;966. doi:10.1053/j.ajkd.2016.07.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2016.07.026</ArticleId><ArticleId IdType="pubmed">27663040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol. 2009;5(4):212&#x2013;220. doi:10.1038/nrneph.2009.14</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2009.14</ArticleId><ArticleId IdType="pubmed">19322186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudose S, Santoriello D, Bomback AS, Stokes MB, D'Agati VD, Markowitz GS. Sensitivity and specificity of pathologic findings to diagnose lupus nephritis. Clin J Am Soc Nephrol. 2019;14(11):1605&#x2013;1615. doi:10.2215/CJN.01570219</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01570219</ArticleId><ArticleId IdType="pmc">PMC6832038</ArticleId><ArticleId IdType="pubmed">31653670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J Croom N Troxell ML, et al. . Non-Full House membranous lupus nephritis represents a clinically distinct subset. Kidney360. 2023;4(7):935&#x2013;942. doi:10.34067/KID.0000000000000161</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0000000000000161</ArticleId><ArticleId IdType="pmc">PMC10371271</ArticleId><ArticleId IdType="pubmed">37257088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F Yu J Zhang L, et al. . Clinical relevance of glomerular IgM deposition in patients with lupus nephritis. BMC Immunol. 2021;22(1):75. doi:10.1186/s12865-021-00467-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-021-00467-z</ArticleId><ArticleId IdType="pmc">PMC8650561</ArticleId><ArticleId IdType="pubmed">34876020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MK Maeng YI Lee SJ, et al. . Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways. Int J Clin Exp Pathol.
2013;6(10):2157&#x2013;2167. eCollection 2013. https://pubmed.ncbi.nlm.nih.gov/24133594/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3796238</ArticleId><ArticleId IdType="pubmed">24133594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H Kim T Kim M, et al. . Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis. Lupus. 2020;29(8):862&#x2013;871. doi:10.1177/0961203320925165</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320925165</ArticleId><ArticleId IdType="pubmed">32408850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S Madden BJ Debiec H, et al. . Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol. 2019;30(6):1123&#x2013;1136. doi:10.1681/ASN.2018080852</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2018080852</ArticleId><ArticleId IdType="pmc">PMC6551791</ArticleId><ArticleId IdType="pubmed">31061139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran A Casal Moura M Fervenza FC, et al. . In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J Am Soc Nephrol. 2021;32(3):695&#x2013;706. doi:10.1681/ASN.2020081181</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020081181</ArticleId><ArticleId IdType="pmc">PMC7920177</ArticleId><ArticleId IdType="pubmed">33478971</ArticleId></ArticleIdList></Reference><Reference><Citation>Caza TN Hassen SI Kuperman M, et al. . Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int. 2021;100(1):171&#x2013;181. doi:10.1016/j.kint.2020.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC8032825</ArticleId><ArticleId IdType="pubmed">33045259</ArticleId></ArticleIdList></Reference><Reference><Citation>Caza TN Hassen SI Kenan DJ, et al. . Transforming growth factor beta receptor 3 (TGFBR3)-associated membranous nephropathy. Kidney360. 2021;2(8):1275&#x2013;1286. doi:10.34067/KID.0001492021</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0001492021</ArticleId><ArticleId IdType="pmc">PMC8676385</ArticleId><ArticleId IdType="pubmed">35369660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>